Europe
Using gene therapy to edit embryos, sperm or eggs in order to improve health conditions in a child should not be conducted due to the unreliability of the science, as well as due to significant ethical and moral concerns.Those are the words found in new guidance established this week.
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
As we head into cold and flu season, the question arises: Can you get COVID-19 and the flu at the same time?
It’s entirely possible that what we will be seeing most from the U.S. Food and Drug Administration for the month of September is related to treatments and vaccines for COVID-19.
Treatments for COVID-19 may be focusing on at the wrong elements of the disease, according to physicians analyzing results from Bergamo, Italy, the epicenter of the pandemic in Europe.
Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
A study published in the journal npj Precision Oncology on Sept. 1 featured data that suggested honeybee venom can potentially destroy triple-negative breast cancer and HER2-enriched breast cancer cells.
GlaxoSmithKline has opened a new $13 million research hub in London focused on artificial intelligence.
PRESS RELEASES